Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.
Identifieur interne : 000C56 ( Ncbi/Merge ); précédent : 000C55; suivant : 000C57Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.
Auteurs : Robert L. Kruse [États-Unis]Source :
- F1000Research [ 2046-1402 ] ; 2020.
Descripteurs français
- KwdFr :
- Anticorps monoclonaux (usage thérapeutique), Anticorps neutralisants (usage thérapeutique), Chine (épidémiologie), Essais cliniques à usage compassionnel, Flambées de maladies, Humains, Infections à coronavirus (traitement médicamenteux), Oligonucléotides (usage thérapeutique), Peptidyl-Dipeptidase A (), Pneumopathie virale (traitement médicamenteux), Repositionnement des médicaments.
- MESH :
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Anticorps monoclonaux, Anticorps neutralisants, Oligonucléotides.
- épidémiologie : Chine.
- Essais cliniques à usage compassionnel, Flambées de maladies, Humains, Peptidyl-Dipeptidase A, Repositionnement des médicaments.
- Wicri :
- geographic : République populaire de Chine.
English descriptors
- KwdEn :
- Antibodies, Monoclonal (therapeutic use), Antibodies, Neutralizing (therapeutic use), Betacoronavirus (drug effects), China (epidemiology), Compassionate Use Trials, Coronavirus Infections (drug therapy), Disease Outbreaks, Drug Repositioning, Humans, Oligonucleotides (therapeutic use), Peptidyl-Dipeptidase A (drug effects), Pneumonia, Viral (drug therapy).
- MESH :
- chemical , drug effects : Peptidyl-Dipeptidase A.
- chemical , therapeutic use : Antibodies, Monoclonal, Antibodies, Neutralizing, Oligonucleotides.
- geographic , epidemiology : China.
- drug effects : Betacoronavirus.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- Compassionate Use Trials, Disease Outbreaks, Drug Repositioning, Humans.
Abstract
A novel coronavirus (2019-nCoV) originating in Wuhan, China presents a potential respiratory viral pandemic to the world population. Current efforts are focused on containment and quarantine of infected individuals. Ultimately, the outbreak could be controlled with a protective vaccine to prevent 2019-nCoV infection. While vaccine research should be pursued intensely, there exists today no therapy to treat 2019-nCoV upon infection, despite an urgent need to find options to help these patients and preclude potential death. Herein, I review the potential options to treat 2019-nCoV in patients, with an emphasis on the necessity for speed and timeliness in developing new and effective therapies in this outbreak. I consider the options of drug repurposing, developing neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advocate for the fastest strategy to develop a treatment now, which could be resistant to any mutations the virus may have in the future. The proposal is a biologic that blocks 2019-nCoV entry using a soluble version of the viral receptor, angiotensin-converting enzyme 2 (ACE2), fused to an immunoglobulin Fc domain, providing a neutralizing antibody with maximal breath to avoid any viral escape, while also helping to recruit the immune system to build lasting immunity. The sequence of the ACE2-Fc protein is provided to investigators, allowing its possible use in recombinant protein expression systems to start producing drug today to treat patients under compassionate use, while formal clinical trials are later undertaken. Such a treatment could help infected patients before a protective vaccine is developed and widely available in the coming months to year(s).
DOI: 10.12688/f1000research.22211.2
PubMed: 32117569
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000915
- to stream PubMed, to step Curation: 000915
- to stream PubMed, to step Checkpoint: 000209
Links to Exploration step
pubmed:32117569Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.</title><author><name sortKey="Kruse, Robert L" sort="Kruse, Robert L" uniqKey="Kruse R" first="Robert L" last="Kruse">Robert L. Kruse</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland, 21287, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland, 21287</wicri:regionArea><wicri:noRegion>21287</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32117569</idno><idno type="pmid">32117569</idno><idno type="doi">10.12688/f1000research.22211.2</idno><idno type="wicri:Area/PubMed/Corpus">000915</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000915</idno><idno type="wicri:Area/PubMed/Curation">000915</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000915</idno><idno type="wicri:Area/PubMed/Checkpoint">000209</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000209</idno><idno type="wicri:Area/Ncbi/Merge">000C56</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.</title><author><name sortKey="Kruse, Robert L" sort="Kruse, Robert L" uniqKey="Kruse R" first="Robert L" last="Kruse">Robert L. Kruse</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland, 21287, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland, 21287</wicri:regionArea><wicri:noRegion>21287</wicri:noRegion></affiliation></author></analytic><series><title level="j">F1000Research</title><idno type="eISSN">2046-1402</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antibodies, Neutralizing (therapeutic use)</term><term>Betacoronavirus (drug effects)</term><term>China (epidemiology)</term><term>Compassionate Use Trials</term><term>Coronavirus Infections (drug therapy)</term><term>Disease Outbreaks</term><term>Drug Repositioning</term><term>Humans</term><term>Oligonucleotides (therapeutic use)</term><term>Peptidyl-Dipeptidase A (drug effects)</term><term>Pneumonia, Viral (drug therapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Anticorps neutralisants (usage thérapeutique)</term><term>Chine (épidémiologie)</term><term>Essais cliniques à usage compassionnel</term><term>Flambées de maladies</term><term>Humains</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Oligonucléotides (usage thérapeutique)</term><term>Peptidyl-Dipeptidase A ()</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Repositionnement des médicaments</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Peptidyl-Dipeptidase A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Neutralizing</term><term>Oligonucleotides</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>China</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Anticorps neutralisants</term><term>Oligonucléotides</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Chine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Compassionate Use Trials</term><term>Disease Outbreaks</term><term>Drug Repositioning</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Essais cliniques à usage compassionnel</term><term>Flambées de maladies</term><term>Humains</term><term>Peptidyl-Dipeptidase A</term><term>Repositionnement des médicaments</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>République populaire de Chine</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A novel coronavirus (2019-nCoV) originating in Wuhan, China presents a potential respiratory viral pandemic to the world population. Current efforts are focused on containment and quarantine of infected individuals. Ultimately, the outbreak could be controlled with a protective vaccine to prevent 2019-nCoV infection. While vaccine research should be pursued intensely, there exists today no therapy to treat 2019-nCoV upon infection, despite an urgent need to find options to help these patients and preclude potential death. Herein, I review the potential options to treat 2019-nCoV in patients, with an emphasis on the necessity for speed and timeliness in developing new and effective therapies in this outbreak. I consider the options of drug repurposing, developing neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advocate for the fastest strategy to develop a treatment now, which could be resistant to any mutations the virus may have in the future. The proposal is a biologic that blocks 2019-nCoV entry using a soluble version of the viral receptor, angiotensin-converting enzyme 2 (ACE2), fused to an immunoglobulin Fc domain, providing a neutralizing antibody with maximal breath to avoid any viral escape, while also helping to recruit the immune system to build lasting immunity. The sequence of the ACE2-Fc protein is provided to investigators, allowing its possible use in recombinant protein expression systems to start producing drug today to treat patients under compassionate use, while formal clinical trials are later undertaken. Such a treatment could help infected patients before a protective vaccine is developed and widely available in the coming months to year(s).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32117569</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>20</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2046-1402</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>F1000Research</Title><ISOAbbreviation>F1000Res</ISOAbbreviation></Journal><ArticleTitle>Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.</ArticleTitle><Pagination><MedlinePgn>72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.12688/f1000research.22211.2</ELocationID><Abstract><AbstractText>A novel coronavirus (2019-nCoV) originating in Wuhan, China presents a potential respiratory viral pandemic to the world population. Current efforts are focused on containment and quarantine of infected individuals. Ultimately, the outbreak could be controlled with a protective vaccine to prevent 2019-nCoV infection. While vaccine research should be pursued intensely, there exists today no therapy to treat 2019-nCoV upon infection, despite an urgent need to find options to help these patients and preclude potential death. Herein, I review the potential options to treat 2019-nCoV in patients, with an emphasis on the necessity for speed and timeliness in developing new and effective therapies in this outbreak. I consider the options of drug repurposing, developing neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advocate for the fastest strategy to develop a treatment now, which could be resistant to any mutations the virus may have in the future. The proposal is a biologic that blocks 2019-nCoV entry using a soluble version of the viral receptor, angiotensin-converting enzyme 2 (ACE2), fused to an immunoglobulin Fc domain, providing a neutralizing antibody with maximal breath to avoid any viral escape, while also helping to recruit the immune system to build lasting immunity. The sequence of the ACE2-Fc protein is provided to investigators, allowing its possible use in recombinant protein expression systems to start producing drug today to treat patients under compassionate use, while formal clinical trials are later undertaken. Such a treatment could help infected patients before a protective vaccine is developed and widely available in the coming months to year(s).</AbstractText><CopyrightInformation>Copyright: © 2020 Kruse RL.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kruse</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials><Identifier Source="ORCID">0000-0002-8669-6242</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland, 21287, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>F1000Res</MedlineTA><NlmUniqueID>101594320</NlmUniqueID><ISSNLinking>2046-1402</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009841">Oligonucleotides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber><NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.-</RegistryNumber><NameOfSubstance UI="C413524">angiotensin converting enzyme 2</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="Y">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057176" MajorTopicYN="N">Compassionate Use Trials</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="Y">Drug Repositioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009841" MajorTopicYN="N">Oligonucleotides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">2019-nCoV</Keyword><Keyword MajorTopicYN="Y">ACE2</Keyword><Keyword MajorTopicYN="Y">Wuhan</Keyword><Keyword MajorTopicYN="Y">coronavirus</Keyword><Keyword MajorTopicYN="Y">neutralizing antibody</Keyword><Keyword MajorTopicYN="Y">outbreak</Keyword></KeywordList><CoiStatement>No competing interests were disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>01</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32117569</ArticleId><ArticleId IdType="doi">10.12688/f1000research.22211.2</ArticleId><ArticleId IdType="pmc">PMC7029759</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>PLoS One. 2013 Dec 04;8(12):e81587</Citation><ArticleIdList><ArticleId IdType="pubmed">24324708</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2000 Jul;182(1):326-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10882617</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Thorax. 2004 Mar;59(3):252-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14985565</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Pathog. 2015 Apr 23;11(4):e1004717</Citation><ArticleIdList><ArticleId IdType="pubmed">25905897</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Arch Virol Suppl. 1996;11:135-40</Citation><ArticleIdList><ArticleId IdType="pubmed">8800795</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93</Citation><ArticleIdList><ArticleId IdType="pubmed">24841273</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Microbiol. 2003 Dec;1(3):209-18</Citation><ArticleIdList><ArticleId IdType="pubmed">15035025</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2020 Feb 15;395(10223):514-523</Citation><ArticleIdList><ArticleId IdType="pubmed">31986261</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Anticancer Res. 2010 Oct;30(10):4353-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21036763</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Commun. 2014 May 06;5:3594</Citation><ArticleIdList><ArticleId IdType="pubmed">24800825</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Oct;78(19):10628-35</Citation><ArticleIdList><ArticleId IdType="pubmed">15367630</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Kona. 2016 Feb 28;33:63-85</Citation><ArticleIdList><ArticleId IdType="pubmed">27081214</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Methods Mol Biol. 2019;1911:395-419</Citation><ArticleIdList><ArticleId IdType="pubmed">30593641</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>CMAJ. 2003 Jun 24;168(13):1649-60</Citation><ArticleIdList><ArticleId IdType="pubmed">12821618</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>F1000Res. 2015 Feb 09;4:38</Citation><ArticleIdList><ArticleId IdType="pubmed">25713700</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Med. 2016 Apr 19;13(4):e1001997</Citation><ArticleIdList><ArticleId IdType="pubmed">27093560</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>NPJ Vaccines. 2018 Oct 5;3:42</Citation><ArticleIdList><ArticleId IdType="pubmed">30323953</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2020 Feb 20;382(8):727-733</Citation><ArticleIdList><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2017 Feb 4;389(10068):505-518</Citation><ArticleIdList><ArticleId IdType="pubmed">28017403</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Rev Med Virol. 2018 Jul;28(4):e1976</Citation><ArticleIdList><ArticleId IdType="pubmed">29656441</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Drug Discov Today. 2019 Mar;24(3):726-736</Citation><ArticleIdList><ArticleId IdType="pubmed">30711575</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Microbiol Biotechnol. 2019 Apr 28;29(4):651-657</Citation><ArticleIdList><ArticleId IdType="pubmed">30856707</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Rep. 2017 Aug 21;7(1):8390</Citation><ArticleIdList><ArticleId IdType="pubmed">28827559</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2004 Jan 30;279(5):3197-201</Citation><ArticleIdList><ArticleId IdType="pubmed">14670965</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Pharm Des. 2006;12(11):1339-55</Citation><ArticleIdList><ArticleId IdType="pubmed">16611119</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Immunol. 2018 May;18(5):297-308</Citation><ArticleIdList><ArticleId IdType="pubmed">29379211</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>EMBO J. 2005 Apr 20;24(8):1634-43</Citation><ArticleIdList><ArticleId IdType="pubmed">15791205</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Crit Care. 2017 Sep 7;21(1):234</Citation><ArticleIdList><ArticleId IdType="pubmed">28877748</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2014 Apr;454-455:157-68</Citation><ArticleIdList><ArticleId IdType="pubmed">24725942</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2012;7(11):e50366</Citation><ArticleIdList><ArticleId IdType="pubmed">23185609</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2013 Mar 14;495(7440):251-4</Citation><ArticleIdList><ArticleId IdType="pubmed">23486063</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2020 Jan 31;94(4):</Citation><ArticleIdList><ArticleId IdType="pubmed">31776280</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int J Cancer Suppl. 1992;7:69-72</Citation><ArticleIdList><ArticleId IdType="pubmed">1428410</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2005 Jul 7;436(7047):112-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16001071</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2016 Oct 13;375(15):1448-1456</Citation><ArticleIdList><ArticleId IdType="pubmed">27732819</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):E1371-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23530214</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Adv Virus Res. 2019;105:93-116</Citation><ArticleIdList><ArticleId IdType="pubmed">31522710</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Nov 12;324(2):773-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15474494</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2016 Feb 18;374(7):636-46</Citation><ArticleIdList><ArticleId IdType="pubmed">26886522</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2015 May 21;521(7552):362-5</Citation><ArticleIdList><ArticleId IdType="pubmed">25901685</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Rep. 2016 Jan 27;6:19840</Citation><ArticleIdList><ArticleId IdType="pubmed">26813885</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Commun. 2020 Jan 10;11(1):222</Citation><ArticleIdList><ArticleId IdType="pubmed">31924756</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation><ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Transl Med. 2019 Nov 27;11(520):</Citation><ArticleIdList><ArticleId IdType="pubmed">31776287</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2005 Sep 16;309(5742):1864-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16166518</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2015 Mar 5;519(7541):87-91</Citation><ArticleIdList><ArticleId IdType="pubmed">25707797</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Infect Dis. 2015 Aug 15;61(4):496-502</Citation><ArticleIdList><ArticleId IdType="pubmed">25904375</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Am J Pathol. 2007 Apr;170(4):1136-47</Citation><ArticleIdList><ArticleId IdType="pubmed">17392154</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Kidney Int. 2018 Jul;94(1):114-125</Citation><ArticleIdList><ArticleId IdType="pubmed">29691064</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2004 Jun 3;350(23):2352-61</Citation><ArticleIdList><ArticleId IdType="pubmed">15175437</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2005 Aug;11(8):875-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16007097</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Hosp Infect. 2020 Jan 18;:</Citation><ArticleIdList><ArticleId IdType="pubmed">31962139</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2016 Oct 15;214(suppl 3):S367-S374</Citation><ArticleIdList><ArticleId IdType="pubmed">27571900</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Front Bioeng Biotechnol. 2019 Dec 20;7:420</Citation><ArticleIdList><ArticleId IdType="pubmed">31921823</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Protein Cell. 2018 Jan;9(1):63-73</Citation><ArticleIdList><ArticleId IdType="pubmed">28986820</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Microbiol. 2016 Aug 22;1(10):16142</Citation><ArticleIdList><ArticleId IdType="pubmed">27670117</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Blood Transfus. 2016 Mar;14(2):152-7</Citation><ArticleIdList><ArticleId IdType="pubmed">26674811</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Handb Exp Pharmacol. 2009;(189):85-110</Citation><ArticleIdList><ArticleId IdType="pubmed">19048198</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Drug Discov Today. 2015 Jul;20(7):794-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25701282</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Front Immunol. 2017 Nov 20;8:1589</Citation><ArticleIdList><ArticleId IdType="pubmed">29209322</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Opin Immunol. 2016 Jun;40:78-87</Citation><ArticleIdList><ArticleId IdType="pubmed">27038127</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Card Fail. 2013 Sep;19(9):605-10</Citation><ArticleIdList><ArticleId IdType="pubmed">24054336</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Pathog. 2008 Nov;4(11):e1000225</Citation><ArticleIdList><ArticleId IdType="pubmed">19043556</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Ther. 2015 Nov 1;37(11):2402-2410</Citation><ArticleIdList><ArticleId IdType="pubmed">26452427</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Transl Med. 2019 Jul 24;11(502):</Citation><ArticleIdList><ArticleId IdType="pubmed">31341061</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2536-41</Citation><ArticleIdList><ArticleId IdType="pubmed">14983044</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2000 Dec;182(6):1774-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11069253</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2020 Feb 14;94(5):</Citation><ArticleIdList><ArticleId IdType="pubmed">31826992</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Pharmacokinet. 2013 Sep;52(9):783-92</Citation><ArticleIdList><ArticleId IdType="pubmed">23681967</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2010 Jan;84(2):1198-205</Citation><ArticleIdList><ArticleId IdType="pubmed">19864379</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country></list><tree><country name="États-Unis"><noRegion><name sortKey="Kruse, Robert L" sort="Kruse, Robert L" uniqKey="Kruse R" first="Robert L" last="Kruse">Robert L. Kruse</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C56 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000C56 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:32117569
|texte= Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:32117569" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a CovidV2
| This area was generated with Dilib version V0.6.33. |  |